Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06053658 · ClinicalTrials.gov registry record · Phase 2

Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma

A Phase 2 study of Renal Cell Carcinoma, sponsored by M.D. Anderson Cancer Center.

Recruiting
Registry status
Phase 2
Development phase
48
Enrollment target
5
Study locations

NCT06053658 is a Phase 2 study of Renal Cell Carcinoma that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 48 participants, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (80% lower). The trial reports 5 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06053658, a Phase 2 study of Renal Cell Carcinoma, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.

RECRUITING
Registry status
Phase 2
Development phase
48 participants
Enrollment target
5
Study locations

Study Summary

To learn if giving tivozanib in combination with nivolumab can help to control advanced nccRCC.

Conditions Studied

Renal Cell Carcinoma

Interventions

  • DRUG Nivolumab
  • DRUG Tivozanib

Study Locations (5)

Massachusetts

  • Beth Israel Deaconess Medical Center - Boston
  • Dana-Farber Cancer Institute - Boston

Texas

  • UT Southwestern Medical Center - Dallas
  • M D Anderson Cancer Center - Houston

Michigan

  • University of Michigan - Ann Arbor

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2024-01-05
Est. Completion 2028-11-01
Phase Phase 2

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06053658

The ClinicalTrials.gov registry entry for NCT06053658 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (80% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.

NCT06053658 reports 5 study locations spanning 3 distinct geographic areas - top geographies include Massachusetts, Texas, Michigan.

Frequently Asked Questions

What is clinical trial NCT06053658 about?

NCT06053658 is a clinical study titled "Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma". To learn if giving tivozanib in combination with nivolumab can help to control advanced nccRCC.

What is the current status of trial NCT06053658?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2024-01-05. Estimated completion is 2028-11-01.

What conditions does trial NCT06053658 study?

This clinical trial studies the following conditions: Renal Cell Carcinoma.

What interventions are being tested in trial NCT06053658?

The interventions under investigation include: Nivolumab (DRUG), Tivozanib (DRUG).

Who is sponsoring clinical trial NCT06053658?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06053658 being conducted?

This trial has 5 study locations across Massachusetts, Michigan, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Renal Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Renal Cell Carcinoma

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.